ScinoPharm Taiwan

ScinoPharm Taiwan’s CGMP API manufacturing facilities in Taiwan and Changshu, China meet global quality standards recognized by US FDA, Japan PMDA, and other authorities.

ScinoPharm Taiwan develops and manufactures small molecules and peptide drugs, with regulatory submissions for products like Abemaciclib, Alectinib HCl, and Apixaban.

Service ScopeIdentification of Nitrosamine Impurities using High-Resolution Mass Spectrometry (HR-MS)Elemental impurityPhysicochemical Characterization: XRPD, NMR, SEM, DSC, EDS, DVSExtractable&Leachable (E&L) (Under Preparation)Other Contract Analytical Testing ServicesCompliant with cGMP, PICS/GMP

ContentsMultiple SclerosisAnticancerThromboembolic Disorders Multiple SclerosisNameDescriptionGlatiramer AcetateUS FDA ANDA approvedStrength: 20MG/1.0ML; 40MG/1.0MLDosage form: pre-filled syringe for injection AnticancerNameDescriptionBortezomibTaiwan: BORZOTaiwan FDA ApprovedStrength: 3.5MG/VIALDosage form: lyophilized powderTaiwan FDA license number : 衛部藥製字第062089號ClofarabineStrength: 20MG/20MLDosage form: liquid solution Th..

ScinoPharm Taiwan’s annual arts lecture series, ScinoPharm Arts Forum, concluded its 17th consecutive year in October 2024, engaging the local community.

ScinoPharm Taiwan reported consolidated revenue of US$42.3 million and NT$1,338 million for the first half of 2026, with API business supported by product optimization and cost improvements.

ScinoPharm Taiwan reported 2025 consolidated revenue of NT$3.163 billion, net profit of NT$137 million, and earnings per share of NT$0.17 through product mix optimization.

ScinoPharm Taiwan lists job openings on 104 Job Bank and invites resumes via email.

ScinoPharm Taiwan values employees as its most important asset, fostering a workplace built on trust and collaboration.

ScinoPharm Taiwan offers competitive, performance-based compensation, flexible working hours, and additional paid leave.

ScinoPharm Taiwan elects 17 directors for three-year terms. The Board of Directors oversees company decisions, while the Chairman leads meetings and the CEO implements operations.

Table of ContentsAudit CommitteeRemuneration CommitteeAudit Committee

ScinoPharm communicates with shareholders and investors through annual meetings and regulatory disclosures, including 22 announcements in 2025.

ScinoPharm conducted an employee opinion survey in December 2025 to gather feedback on career development.

DocumentInternal AuditDownloadCorporate Governance Implementation StatusDownload

ScinoPharm Taiwan provides investor and shareholder contact details, including names, phone numbers, and addresses in Tainan.

ScinoPharm Taiwan prioritizes high-potency APIs with technical barriers, using CGMP facilities to avoid patent conflicts and develop proprietary processes.

ScinoPharm Taiwan wins two 2026 CommonWealth Sustainability Awards: 13th place in the Small Giants category for Corporate Social Responsibility and the Talent Sustainability Award. The company earns its third consecutive Small Giants recognition, highlighting ongoing sustainability initiatives and workforce development.

Oct 2026ScinoPharm Taiwan, Ltd.News article

ScinoPharm Taiwan reports **H1 2026 revenue of $42.3M (NT$1.34B)** while optimizing its API business through product portfolio adjustments and cost improvements. Gross margins benefit from core products, though profitability faces headwinds from slower customer sales, production rescheduling, and operational shortfalls. The company continues refining capacity allocation across its three key business pillars.

Aug 2026ScinoPharm Taiwan, Ltd.News article

ScinoPharm Taiwan reports **NT$3.163 billion in 2025 revenue**, with a net profit of **NT$137 million** and **EPS of NT$0.17**. The company maintains stable gross margins through product mix optimization and cost control. It addresses global supply chain challenges by aligning with government pharmaceutical policies to bolster local resilience amid currency volatility.

Mar 2026ScinoPharm Taiwan, Ltd.News article

ScinoPharm Taiwan wins Taiwan Food and Drug Administration (TFDA) approval for Bortezomib, a multiple myeloma treatment. The company follows its 2023 U.S. FDA approval, reinforcing its oncology drug development capabilities. This approval aligns with Taiwan’s pharmaceutical supply chain resilience initiatives.

Jan 2026ScinoPharm Taiwan, Ltd.News article